1-20 of 34
Leif W. Ellisen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 960: Overlapping expression landscape of antibody drug conjugate targets, trophoblast cell surface antigen 2 (Trop-2) & human epidermal growth factor receptor 2 (HER2), in breast cancer

Arielle J. Medford, Nicholas J. Haradhvala, Neelima Vidula, Rachel Abelman, Laura M. Spring, Leif W. Ellisen, Gad Getz, Aditya Bardia
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 960.
https://doi.org/10.1158/1538-7445.AM2023-960
Published: 04 April 2023
View article titled, Abstract 960: Overlapping expression landscape of antibody drug conjugate targets, trophoblast cell surface antigen 2 (Trop-2) & human epidermal growth factor receptor 2 (HER2), in breast cancer
Journal Articles

Abstract 3680: Multiomics analysis of triple negative breast cancer identifies potential metabolic vulnerability for overcoming the resistance of neoadjuvant therapy

Zuen Ren, Kiran Kurmi, Robert Morris, Shakchhi Joshi, Eric Zaniewski, Johannes Kreuzer, Gabrielle Elena Gioia, Wilhelm Haas, Marcia C. Haigis, Leif W. Ellisen
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3680.
https://doi.org/10.1158/1538-7445.AM2023-3680
Published: 04 April 2023
View article titled, Abstract 3680: Multiomics analysis of triple negative breast cancer identifies potential metabolic vulnerability for overcoming the resistance of neoadjuvant therapy
Journal Articles

Abstract 767: Genomics and transcriptomics profiling of BRCA mutation carriers revealed the landscape of early pathogenesis of BRCA1/2-associated breast cancer

Zuen Ren, Po-Han Lin, Siang Boon Koh, Kai Stewart, Nick Haradhvala, Aylin S Dedeoglu, Ilze Smidt, Akiko Suzuki, David Li, Win Thant, Sarah Mueller, Taisha Joseph, Veerle Bossuyt, Michael Lawrence, Gad Getz, Leif W. Ellisen
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 767.
https://doi.org/10.1158/1538-7445.AM2023-767
Published: 04 April 2023
View article titled, Abstract 767: Genomics and transcriptomics profiling of BRCA mutation carriers revealed the landscape of early pathogenesis of BRCA1/2-associated breast cancer
Journal Articles

Abstract 5248: CDK4/6 inhibition (CDK4/6i) is effective in the real-world setting for hormone receptor-positive metastatic breast cancer (HR+ MBC) with ESR1 mutations and fusions

Jamie O. Brett, Caroline M. Weipert, Lauren L. Ritterhouse, Nicole Zhang, Junhua Yu, Lianne Y. Ryan, Laura M. Spring, Miguel N. Rivera, Jochen K. Lennerz, Dora Dias-Santagata, Leif W. Ellisen, Aditya Bardia, Seth A. Wander
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 5248.
https://doi.org/10.1158/1538-7445.AM2022-5248
Published: 15 June 2022
View article titled, Abstract 5248: CDK4/6 inhibition (CDK4/6i) is effective in the real-world setting for hormone receptor-positive metastatic breast cancer (HR+ MBC) with <em>ESR1</em> mutations and fusions
Journal Articles

Abstract P3-09-11: Clinical characteristics associated withBRCA1/2mutations identified on routine tumor tissue genotyping in metastatic breast cancer

Neelima Vidula, Erica Blouch, Alexander Farahani, Hetal Marble, Andrzej Niemierko, Kathleen Hesler, Elyssa Denault, Dejan Juric, Leif W. Ellisen, Beverly Moy, Steven Isakoff, Jochen Lennerz, Aditya Bardia
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P3-09-11.
https://doi.org/10.1158/1538-7445.SABCS21-P3-09-11
Published: 15 February 2022
View article titled, Abstract P3-09-11: Clinical characteristics associated with<em>BRCA1/2</em>mutations identified on routine tumor tissue genotyping in metastatic breast cancer
Journal Articles

Abstract OT2-24-03: Phase II study of a PARP inhibitor in metastatic breast cancer with somaticBRCA1/2mutations identified by cell-free DNA: Genotyping based clinical trial

Neelima Vidula, Erica Blouch, Erin Basile, Nathan Royce Ruffle-Deignan, Nora Horick, Senthil Damodaran, Alvaro Moreno Aspitia, Manali Bhave, Ami Shah, Minetta C. Liu, Joseph Sparano, Harry Ostrer, Hope Rugo, Leif W. Ellisen, Aditya Bardia
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): OT2-24-03.
https://doi.org/10.1158/1538-7445.SABCS21-OT2-24-03
Published: 15 February 2022
View article titled, Abstract OT2-24-03: Phase II study of a PARP inhibitor in metastatic breast cancer with somatic<em>BRCA1/2</em>mutations identified by cell-free DNA: Genotyping based clinical trial
Journal Articles

Abstract P1-18-22: AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigation

Seth A. Wander, Douglas S. Micalizzi, Taronish Dubash, Dejan Juric, Laura M. Spring, Neelima Vidula, Jennifer Keenan, Maureen Beeler, Elene Viscosi, Dante Che, Elizabeth L. Fisher, Rachel A. Hepp, Beverly Moy, Steven J. Isakoff, Leif W. Ellisen, Jeffrey G. Supko, Shyamala Maheswaran, Daniel A. Haber, Aditya Bardia
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P1-18-22.
https://doi.org/10.1158/1538-7445.SABCS21-P1-18-22
Published: 15 February 2022
View article titled, Abstract P1-18-22: AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigation
Journal Articles

Abstract P3-23-02: Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer receiving CDK 4/6 inhibitors

Elyssa Denault, Erika Nakajima, Vivek Naranbhai, Alejandro Balazs, Lindsey Mortensen, Elizabeth Niehoff, Caroline Barabell, Jennifer A. Hutchinson, Seth A. Wander, Aron S. Rosenstock, Leif W. Ellisen, Beverly Moy, Steven J. Isakoff, Justin F. Gainor, A. John Iafrate, Aditya Bardia, Laura M. Spring
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P3-23-02.
https://doi.org/10.1158/1538-7445.SABCS21-P3-23-02
Published: 15 February 2022
View article titled, Abstract P3-23-02: Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer receiving CDK 4/6 inhibitors
Journal Articles

Abstract P5-13-21: Relationship between circulating tumor DNA and response to neoadjuvant niraparib in HER2-negative, BRCA-mutated breast cancer

Ming Shan, Laura Spring, Minetta C Liu, Erika Hamilton, Hanna Irie, Cesar A Santa-Maria, Steven J Isakoff, James Reeves, Leif W Ellisen, Lee P Lim, Kavita Garg, Caterina Bertucci, Bin Feng, Hailei Zhang, Kaiming Sun, Julie R Graham, Erin Hofstatter, Hyo Han
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P5-13-21.
https://doi.org/10.1158/1538-7445.SABCS21-P5-13-21
Published: 15 February 2022
View article titled, Abstract P5-13-21: Relationship between circulating tumor DNA and response to neoadjuvant niraparib in HER2-negative, BRCA-mutated breast cancer
Journal Articles

Abstract PS17-02: Molecular alterations in the androgen receptor and associated clinical outcomes in hormone receptor-positive/HER2- metastatic breast cancer

Charles Dai, Andrzej Niemierko, Neelima Vidula, Laura M Spring, Seth A Wander, Arielle J Medford, Katherine A Hesler, Giuliana Malvarosa, Jeffrey Peppercorn, Dejan Juric, Steven J Isakoff, Beverly Moy, Leif W Ellisen, Aditya Bardia
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS17-02.
https://doi.org/10.1158/1538-7445.SABCS20-PS17-02
Published: 15 February 2021
View article titled, Abstract PS17-02: Molecular alterations in the androgen receptor and associated clinical outcomes in hormone receptor-positive/HER2- metastatic breast cancer
Journal Articles

Abstract OT-30-02: Phase II study of talazoparib, a PARP inhibitor, in somatic BRCA1/2 mutant metastatic breast cancer

Neelima Vidula, Nora Horick, Erin Basile, Erica Blouch, Leif W. Ellisen, Hope S. Rugo, Aditya Bardia
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): OT-30-02.
https://doi.org/10.1158/1538-7445.SABCS20-OT-30-02
Published: 15 February 2021
View article titled, Abstract OT-30-02: Phase II study of talazoparib, a PARP inhibitor, in somatic <em>BRCA1/2</em> mutant metastatic breast cancer
Journal Articles

Abstract PS18-19: Comparison of metastatic genomic profile in patients ≤45 years and patients >45 years with triple-negative breast cancer

Neelima Vidula, Andrzej Niemierko, Katherine Hesler, Steven Isakoff, Dejan Juric, Jennifer Shin, Laura Spring, Jeffrey Peppercorn, Jerry Younger, Irene Kuter, Beverly Moy, Leif W. Ellisen, Aditya Bardia
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS18-19.
https://doi.org/10.1158/1538-7445.SABCS20-PS18-19
Published: 15 February 2021
View article titled, Abstract PS18-19: Comparison of metastatic genomic profile in patients ≤45 years and patients &gt;45 years with triple-negative breast cancer
Journal Articles

Abstract OT-03-06: Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer (NeoSTAR)

Laura M. Spring, Sara M. Tolaney, Neelam Desai, Amy Comander, Therese Mulvey, Ian E. Krop, Eric P. Winer, Elizabeth A. Mittendorf, Leif W. Ellisen, Aditya Bardia
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): OT-03-06.
https://doi.org/10.1158/1538-7445.SABCS20-OT-03-06
Published: 15 February 2021
View article titled, Abstract OT-03-06: Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer (NeoSTAR)
Journal Articles

Abstract 1903: PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Ká inhibitors in breast cancer

Carlotta Costa, Ye Wang, Amy Ly, Yasuyuki Hosono, Ellen Murchie, Charlotte S. Walmsley, Tiffany Huynh, Christopher Healy, Rachel Peterson, Shogo Yanase, Charles T. Jakubik, Laura E. Henderson, Leah J. Damon, Daria Timonina, Ioannis Sanidas, Christopher J. Pinto, Mari Mino-Kenudson, James Stone, Nicholas J. Dyson, Leif W. Ellisen, Aditya Bardia, Hiromichi Ebi, Cyril H. Benes, Jeffrey A. Engelman, Dejan Juric
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 1903.
https://doi.org/10.1158/1538-7445.AM2020-1903
Published: 15 August 2020
View article titled, Abstract 1903: PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Ká inhibitors in breast cancer
Journal Articles

Abstract P6-10-08: AKT1 alterations following exposure to endocrine-based therapy in patients with hormone-receptor positive (HR+) metastatic breast cancer (MBC): Clinical and functional implications

Seth Wander, Pingping Mao, Maxwell Lloyd, Kailey Kowalski, Gabriela N. Johnson, Giuliana Malvarosa, Beverly Moy, Leif W. Ellisen, John Iafrate, Nikhil Wagle, Aditya Bardia
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P6-10-08.
https://doi.org/10.1158/1538-7445.SABCS19-P6-10-08
Published: 15 February 2020
View article titled, Abstract P6-10-08: <em>AKT1</em> alterations following exposure to endocrine-based therapy in patients with hormone-receptor positive (HR+) metastatic breast cancer (MBC): Clinical and functional implications
Journal Articles

Abstract P2-21-01: Feasibility of a multidisciplinary diagnostic breast research biopsy project

Kassidy Beyerlin, Christine Edmonds, Siang Boon Koh, Veerle Bossuyt, Annie Ma, Rachel Jimenez, Michelle Specht, Barbara L Smith, Brian Dontchos, Dennis Sgroi, Steven J Isakoff, Constance Lehman, Leif W Ellisen, Laura M Spring
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P2-21-01.
https://doi.org/10.1158/1538-7445.SABCS19-P2-21-01
Published: 15 February 2020
View article titled, Abstract P2-21-01: Feasibility of a multidisciplinary diagnostic breast research biopsy project
Journal Articles

Abstract P3-09-15: A phase 1b study of PVX-410 (PVX) vaccine plus durvalumab (DUR) as adjuvant therapy in HLA-A2+ early stage triple negative breast cancer (eTNBC) to assess safety and immune response

Steven J Isakoff, Sylvia Adams, Hatem H Soliman, Nadine Tung, William T Barry, Jiani Hu, Lorenzo Trippa, Rachel Deering, Joanne Parker, Hannah Park, Elena F Brachtel, Leif W Ellisen, Mariano Severgnini, Doris Peterkin, Sara M Tolaney
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P3-09-15.
https://doi.org/10.1158/1538-7445.SABCS19-P3-09-15
Published: 15 February 2020
View article titled, Abstract P3-09-15: A phase 1b study of PVX-410 (PVX) vaccine plus durvalumab (DUR) as adjuvant therapy in HLA-A2+ early stage triple negative breast cancer (eTNBC) to assess safety and immune response
Journal Articles

Abstract P3-11-03: Pilot neoadjuvant study of niraparib in HER2-negative, BRCA-mutated resectable breast cancer

Hyo Han, Minetta C Liu, Erika Hamilton, Hanna Irie, Cesar A Santa-Maria, James Reeves, Andre Liem, Adrianna Milillo Naraine, Julie Nangia, David Page, Meghan Duncan, Ming Shan, Yongqiang Tang, Julie R Graham, Leif W Ellisen, Steven Isakoff, Laura Spring
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P3-11-03.
https://doi.org/10.1158/1538-7445.SABCS19-P3-11-03
Published: 15 February 2020
View article titled, Abstract P3-11-03: Pilot neoadjuvant study of niraparib in <em>HER2</em>-negative, <em>BRCA</em>-mutated resectable breast cancer
Journal Articles

Abstract OT2-08-01: A phase 1b trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy with/without CDK 4/6 inhibitor for patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) (TAKTIC)

Seth A. Wander, Dejan Juric, Laura M. Spring, Neelima Vidula, Maureen Beeler, Karleen Habin, Elene Viscosi, Lauren Scarpetti, Elizabeth Tripp, Rachel Hepp, Beverly Moy, Steven J. Isakoff, Leif W. Ellisen, Aditya Bardia
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): OT2-08-01.
https://doi.org/10.1158/1538-7445.SABCS19-OT2-08-01
Published: 15 February 2020
View article titled, Abstract OT2-08-01: A phase 1b trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy with/without CDK 4/6 inhibitor for patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) (TAKTIC)
Journal Articles

Abstract 2727: The premalignant state captured in the landscape of somatic mutations can reveal the cancer cell-of-origin

Kirsten Kubler, Rosa Karlic, Nicholas J. Haradhvala, Kyungsik Ha, Jaegil Kim, Maja Kuzman, Wei Jiao, Sitanshu Gakkhar, Kent W. Mouw, Lior Z. Braunstein, Olivier Elemento, Andrew V. Biankin, Ilse Rooman, Mendy Miller, Christopher D. Nogiec, Edward Curry, Mari Mino-Kenudson, Leif W. Ellisen, Robert Brown, Alexander Gusev, Cristian Tomasetti, Hong-Gee Kim, Hwajin Lee, Kristian Vlahovicek, Charles Sawyers, Katherine A. Hoadley, Edwin Cuppen, Amnon Koren, Peter F. Arndt, David N. Louis, Lincoln Stein, William D. Foulkes, Paz Polak, Gad Getz
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 2727.
https://doi.org/10.1158/1538-7445.AM2019-2727
Published: 01 July 2019
View article titled, Abstract 2727: The premalignant state captured in the landscape of somatic mutations can reveal the cancer cell-of-origin